Novel vaccination strategies for the control of mucosal infection - PubMed (original) (raw)
Review
Novel vaccination strategies for the control of mucosal infection
A J Husband. Vaccine. 1993.
Abstract
Enteric disease remains one of the greatest causes of mortality and morbidity in both human and veterinary species. There has been a remarkable lack of success in vaccination to control mucosal disease and it is therefore apparent that novel strategies are required to achieve effective mucosal immunity. Basic studies described in this paper have addressed problems associated with antigen handling and the induction of an immune response in the intestine, and the subsequent dissemination of effector cells and molecules to intestinal and extra-intestinal submucosal regions. Effective induction of IgA responses is dependent on T-cell help and requires cognate interactions between T cells and B cells within organized gut-associated lymphoid tissue (GALT). The delivery of an IgA antibody response to mucosal sites is also a T cell dependent but antigen driven process. The normal route by which antigen is taken up by GALT is via the epithelial surface but antigen presented in this way via villus epithelial cells generates predominantly a suppressor response. Strategies designed to overcome this effect include the use of powerful adjuvants (such as cholera toxin, muramyldipeptide and phorbol esters), the use of immunogenic carriers, or delivery via liposomes, microspheres or genetically engineered viral or bacterial vectors. Alternatively, the feasibility of accessing GALT via the serosal surface by administration of intraperitoneal antigen in oil emulsion has been explored and a vaccine formulation (Auspharm (patent pending)) has been developed which is suitable for IP delivery in commercial applications.
Similar articles
- Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants.
Chin J, San Gil F, Novak M, Eamens G, Djordjevic S, Simecka J, Duncan J, Mullbacher A. Chin J, et al. J Biotechnol. 1996 Jan 26;44(1-3):13-9. doi: 10.1016/0168-1656(95)00099-2. J Biotechnol. 1996. PMID: 8717381 Review. - Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
Mestecky J, Michalek SM, Moldoveanu Z, Russell MW. Mestecky J, et al. Behring Inst Mitt. 1997 Feb;(98):33-43. Behring Inst Mitt. 1997. PMID: 9382757 Review. - Oral vaccine models: multiple delivery systems employing tetanus toxoid.
Jackson RJ, Staats HF, Xu-Amano J, Takahashi I, Kiyono H, Hudson ME, Gilley RM, Chatfield SN, McGhee JR. Jackson RJ, et al. Ann N Y Acad Sci. 1994 Aug 15;730:217-34. doi: 10.1111/j.1749-6632.1994.tb44251.x. Ann N Y Acad Sci. 1994. PMID: 8080173 - Effect of adjuvants on orally administered antigens.
Genco RJ, Linzer R, Evans RT. Genco RJ, et al. Ann N Y Acad Sci. 1983 Jun 30;409:650-68. doi: 10.1111/j.1749-6632.1983.tb26906.x. Ann N Y Acad Sci. 1983. PMID: 6347002 Review. No abstract available. - Lambda display phage as a mucosal vaccine delivery vehicle for peptide antigens.
González-Cano P, Gamage LNA, Marciniuk K, Hayes C, Napper S, Hayes S, Griebel PJ. González-Cano P, et al. Vaccine. 2017 Dec 19;35(52):7256-7263. doi: 10.1016/j.vaccine.2017.11.010. Epub 2017 Nov 16. Vaccine. 2017. PMID: 29153779
Cited by
- Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice.
Zhao H, Li P, Bian L, Zhang W, Jiang C, Chen Y, Kong W, Zhang Y. Zhao H, et al. Int J Mol Sci. 2023 Sep 2;24(17):13587. doi: 10.3390/ijms241713587. Int J Mol Sci. 2023. PMID: 37686393 Free PMC article. - Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.
Moghadam Ariaee F, Tafaghodi M. Moghadam Ariaee F, et al. Iran J Pharm Res. 2012 Summer;11(3):723-32. Iran J Pharm Res. 2012. PMID: 24250499 Free PMC article. - Pathogenic bacteria as vaccine vectors: teaching old bugs new tricks.
Carleton HA. Carleton HA. Yale J Biol Med. 2010 Dec;83(4):217-22. Yale J Biol Med. 2010. PMID: 21165341 Free PMC article. Review. - Mic1-3 Knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep.
Mévélec MN, Ducournau C, Bassuny Ismael A, Olivier M, Sèche E, Lebrun M, Bout D, Dimier-Poisson I. Mévélec MN, et al. Vet Res. 2010 Jul-Aug;41(4):49. doi: 10.1051/vetres/2010021. Epub 2010 Apr 13. Vet Res. 2010. PMID: 20385082 Free PMC article. - Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
Ishii M, Kojima N. Ishii M, et al. Glycoconj J. 2010 Jan;27(1):115-23. doi: 10.1007/s10719-009-9263-8. Epub 2009 Oct 9. Glycoconj J. 2010. PMID: 19816665
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous